NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT01551745 2021-10-19
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Gradalis, Inc.
Phase 2 Completed
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT00022659 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00407563 2012-04-05
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed